Who are Dianthus Therapeutics, Inc.'s main suppliers?

Dianthus Therapeutics, Inc. (DNTH) key suppliers include: WUXI-BIOLOGICS, Ligand Pharmaceuticals Incorporated, Ligand Pharmaceuticals Incorporated, LGNZZ, LGNZZ and 4 more. View the full supplier network at chainsifter.com/chain/DNTH.

Who are Dianthus Therapeutics, Inc.'s major customers?

Dianthus Therapeutics, Inc. (DNTH) key customers include: TENACIA, ZENAS, Ligand Pharmaceuticals Incorporated, Ligand Pharmaceuticals Incorporated, LGNZZ and 7 more. View the full customer network at chainsifter.com/chain/DNTH.

What sector is Dianthus Therapeutics, Inc. in?

Dianthus Therapeutics, Inc. (DNTH) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Dianthus Therapeutics, Inc. Suppliers, Customers & Supply Chain (DNTH)

9Suppliers

12Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Dianthus Therapeutics, Inc. (DNTH) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

25Total relationships

4Distinct source URLs

7High confidence

0.756Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Dianthus Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
WUXI-BIOLOGICS	WUXI-BIOLOGICS	92%	We currently have a sole source relationship with WuXi Biologics for our supply of claseprubart
LGND	Ligand Pharmaceuticals Incorporated	72%	tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net proceeds from the private placement, $39.…
LGND	Ligand Pharmaceuticals Incorporated	72%	Reciprocal relationship from LGND graph: Reciprocal relationship from DNTH graph: tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activ…
LGNZZ	LGNZZ	72%	Reciprocal relationship from LGNZZ graph: Reciprocal relationship from DNTH graph: tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing acti…
LGNZZ	LGNZZ	72%	tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net proceeds from the private placement, $39.…
SNYNF	Sanofi	72%	Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNTH graph: . Commercial Should any of our product candidates be approved for commercialization, we intend to develop a plan to …
SNYNF	Sanofi	72%	. Commercial Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal inf…
ZBIO	Zenas BioPharma, Inc.	72%	. Commercial Should any of our product candidates be approved for commercialization, we intend to develop a plan to commercialize them in the United States and other key markets, through internal inf…
ZBIO	Zenas BioPharma, Inc.	72%	Reciprocal relationship from ZBIO graph: Reciprocal relationship from DNTH graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from DNTH graph: . Commercial Should any of our prod…

Dianthus Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
TENACIA	TENACIA	92%	Pursuant to the Tenacia Option, if Tenacia exercises the option and pays the Company the option exercise fee related to the second antibody sequence, the Company will grant Tenacia an exclusive licen…
ZENAS	ZENAS	90%	The Company assessed the Zenas Agreements in accordance with ASC 606, Revenue from Contracts with Customers (ASC 606), and concluded that it represented a contract with a customer and was within the …
LGND	Ligand Pharmaceuticals Incorporated	72%	Reciprocal relationship from LGND graph: Reciprocal relationship from DNTH graph: Reciprocal relationship from LGND graph: Reciprocal relationship from DNTH graph: tents Cash Flows from Financing Act…
LGND	Ligand Pharmaceuticals Incorporated	72%	tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net proceeds from the private placement, $39.…
LGNZZ	LGNZZ	72%	Reciprocal relationship from LGNZZ graph: Reciprocal relationship from DNTH graph: Reciprocal relationship from LGNZZ graph: Reciprocal relationship from DNTH graph: Reciprocal relationship from LGNZ…
LGNZZ	LGNZZ	72%	tents Cash Flows from Financing Activities For the year ended December 31, 2024, net cash provided by financing activities consisted of $215.3 million of net proceeds from the private placement, $39.…
ZBIO	Zenas BioPharma, Inc.	72%	ature and extent of the potential impacts to our business, results of operations, liquidity and capital resources. For additional information, see the section titled “ Item 1A. Risk Factors ” found e…
ZBIO	Zenas BioPharma, Inc.	72%	Reciprocal relationship from ZBIO graph: Reciprocal relationship from DNTH graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from DNTH graph: ature and extent of the potential i…
ALLOY-THERAPEUTICS-LLC	ALLOY-THERAPEUTICS-LLC	62%	urities and capital expenditures of $0.1 million, partially offset by $127.0 million of proceeds from sales and maturities of investment securities. Cash Flows from Financing Activities For the year …
IONTAS-LIMITED	IONTAS-LIMITED	62%	urities and capital expenditures of $0.1 million, partially offset by $127.0 million of proceeds from sales and maturities of investment securities. Cash Flows from Financing Activities For the year …
NANJING-LEADS-BIOLABS-CO-LTD	NANJING-LEADS-BIOLABS-CO-LTD	62%	(i) certain development milestones and (ii) certain commercial milestones, the Company is obligated to make payments to IONTAS of up to £ 3.1 million (approximately $ 4.1 million based on the March 3…
ZENAS-BIOPHARMA-LIMITED	ZENAS-BIOPHARMA-LIMITED	62%	ature and extent of the potential impacts to our business, results of operations, liquidity and capital resources. For additional information, see the section titled “ Item 1A. Risk Factors ” found e…

Dianthus Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
DNTH-DEBT-9106	Warrants outstanding: 0.001	90%	xbrl warrant detail from xbrl 2025-12-31.
DNTH-DEBT-9107	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2023-12-31.
DNTH-DEBT	Debt stack $1.4M	90%	Market cache reports total debt of $1.4M.

Dianthus Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Dianthus Therapeutics, Inc..

Dianthus Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
DNTH-OWNER-FMR-LLC	FMR LLC	90%	13F overlay lists FMR LLC as top holder; 243 tracked holders.

Dianthus Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
XNCR	Xencor, Inc.	100.00	2
BHC	Bausch Health Companies Inc.	100.00	2
LLY	Eli Lilly and Company	100.00	2
ZBIO	Zenas BioPharma, Inc.	100.00	1	['customer', 'supplier']
BMY	Bristol-Myers Squibb Company	100.00	2
TKPHF	Takeda Pharmaceutical Company Limited	100.00	2
BMYMP	Bristol-Myers Squibb Co	100.00	2
SNYNF	Sanofi	100.00	1	['supplier']
CLYM	Climb Bio, Inc.	100.00	2
VRDN	Viridian Therapeutics, Inc.	100.00	2
NUVB	Nuvation Bio Inc.	100.00	2
LGND	Ligand Pharmaceuticals Incorporated	100.00	1	['customer', 'supplier']
AZN	AstraZeneca PLC	100.00	2
LGNZZ	LIGAND PHARMACEUTICALS INC	100.00	1	['customer', 'supplier']
ZENAS	ZENAS	60.75	1	['receiving']
CYTOF	Altamira Therapeutics Ltd.	50.00	2
DSGN	Design Therapeutics, Inc.	50.00	2
CCEP	Coca-Cola Europacific Partners PLC	50.00	2
ANRO	Alto Neuroscience, Inc.	50.00	2
BSX	Boston Scientific Corporation	50.00	2

Dianthus Therapeutics, Inc. Supply Chain